WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO1998014182) THERAPEUTIC USE OF D-METHIONINE TO REDUCE THE TOXICITY OF PLATINUM-CONTAINING ANTI-TUMOR COMPOUNDS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/1998/014182    International Application No.:    PCT/US1997/018114
Publication Date: 09.04.1998 International Filing Date: 02.10.1997
Chapter 2 Demand Filed:    24.04.1998    
IPC:
A61K 31/10 (2006.01), A61K 31/198 (2006.01), A61K 31/28 (2006.01), A61K 33/24 (2006.01)
Applicants: SOUTHERN ILLINOIS UNIVERSITY [US/US]; P.O. Box 19230, Springfield, IL 62794-9230 (US)
Inventors: CAMPBELL, Kathleen, C., M.; (US)
Agent: ROEDEL, John, K., Jr.; Senniger, Powers, Leavitt & Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US)
Priority Data:
60/027,750 03.10.1996 US
Title (EN) THERAPEUTIC USE OF D-METHIONINE TO REDUCE THE TOXICITY OF PLATINUM-CONTAINING ANTI-TUMOR COMPOUNDS
(FR) UTILISATION THERAPEUTIQUE DE METHIONINE D POUR REDUIRE LA TOXICITE DE COMPOSES ANTITUMORAUX CONTENANT DU PLATINE
Abstract: front page image
(EN)Methods of preventing or reducing hearing or balance loss, damage to ear cells, weight loss, gastrointestinal toxicity, neurotoxicity, alopecia, and prolonging survival in patients undergoing treatment with therapeutically effective amounts of platinum-containing chemotherapeutic agents such as cisplatin are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent. Combinations of these time periods can also be employed.
(FR)L'invention concerne une méthode de prévention ou de réduction de perte de l'ouïe ou de l'équilibre, de dommages causés aux cellules de l'oreille, de perte de poids, de toxicité gastro-intestinale, de neurotoxicité ou d'alopécie, et de prolongement de la durée de vie de patients soumis à un traitement comprenant des quantités thérapeutiquement efficaces d'agents chimiothérapeutiques contenant du platine, tels que la cisplatine. Ces méthodes consistent à administrer une quantité efficace d'un agent protecteur méthionine, tel que la méthionine D, avant l'administration de l'agent chimiothérapeutique contenant le platine, simultanément à cette opération ou après celle-ci. On peut également combiner ces périodes de temps.
Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW.
African Regional Intellectual Property Organization (GH, KE, LS, MW, SD, SZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)